Department of Medicine
Clinical Collaboration Unit Translational Immunology


Address: Otfried-Müller-Str. 10
72076 Tübingen

Administration Office{element.icon}: +49 7071 29-83275{element.icon}: +49 7071 29-4391{element.icon}:

Peptid-basierte Immuntherapie

Scientific focus

In recent years the breakthrough clinical success of T-cell based immunotherapy approaches including advances in allogeneic stem cell transplantation, checkpoint inhibitors, CAR T cells, bispecific antibodies and adoptive T-cell transfer have revolutionized treatment of several malignancies. However, still some patients do not respond to available therapeutic strategies at all, others for limited time only. Remaining challenges to augment efficacy of T cell-based immunotherapy are particularly to improve specificity and increase the frequency of anti-tumor immune responses, to reduce toxicity and to expand the spectrum of targetable cancer entities. A rational and promising approach to achieve this goal is peptide-based immunotherapy, which represents a low side-effect approach relying on specific immune recognition of tumor-associated HLA (human leucocyte antigen) presented peptides.

Our research group works on the direct mass spectrometric analysis of these HLA presented peptides, the so called immunopeptidome of different tumors with the aim to (I) identify and characterize novel tumor-associated HLA-presented antigens, to (II) evaluate the influence of different cancer drugs on the immunopeptidome of tumor cells and to (III) translate these experimental results in a final step into clinical peptide-based immunotherapy concepts for cancer patients. For chronic lymphocytic leukemia (CLL) this goal has already been achieved: The first multicenter patient-individualized peptide vaccination study for the treatment of CLL patients (iVAC-CLL01, NCT02802943) has been established and is successfully recruiting since October 2016. 

  • 2021Best Abstract Award DGHO Jahrestagung Berlin
  • 2020„Poster Award“ of the University Tübingen, research colloquium
  • 2018„Posterpreis“ DGHO Wien
  • 2017“Posterpreis“ of the University Tübingen, research colloquium
  • 2016Young Investigator Award DGHO Leipzig
  • 2015„Posterpreis“ DGHO Basel
    „Württembergischer Krebspreis“, junior award
  • 2014Abstract Achievement Award American Society of Hematology
  • 2013Abstract Achievement Award American Society of Hematology
  • 2012Abstract Achievement Award American Society of Hematology
  • 2011Promotionspreis“ of the Eberhard Karls University Tübingen
    „Ludolf Krehl Promotionspreis“ of the Süddeutschen Gesellschaft für Innere Medizin
  • 2021

    A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

    Jonas S. Heitmann, Tatjana Bilich, Claudia Tandler, Annika Nelde, Yacine Maringer, Maddalena Marconato, Julia Reusch, Simon Jäger, Monika Denk, Marion Richter, Leonard Anton, Lisa Marie Weber, Malte Roerden, Jens Bauer, Jonas Rieth, Marcel Wacker, Sebastian Hörber, Andreas Peter, Christoph Meisner, Imma Fischer, Markus W. Löffler, Julia Karbach, Elke Jäger, Reinhild Klein, Hans-Georg Rammensee, Helmut R. Salih & Juliane S. Walz

  • 2021

    Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia

    Nelde A, Maringer Y, Bilich T, Salih HR, Roerden M, Heitmann JS, Marcu A, Bauer J, Neidert MC, Denzlinger C, Illerhaus G, Aulitzky WE, Rammensee HGR, Walz JS

  • 2021

    Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients

    Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar MS, Peter A, Hörber S, Bauer J, Rieth J, Wacker M, Berner F, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee HGR, Salih HR, Walz JS

  • 2021

    Differential T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune response after COVID-19

    Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, Rieth J, Wacker M, Peter A, Horber S, Rachfalski D, Märklin M, Stevanovic S, Rammensee HG, Salih H, Walz JS

  • 2021

    SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T-cell recognition

    Nelde A, Bilich T, Heitmann JS, Maringer Y, Salih HR, Roerden M, Lübke M, Bauer J, Rieth J, Wacker M, Peter A, Hörber S, Traenkle B, Kaiser PD, Rothbauer U, Becker M, Junker D, Krause G, Strengert S, Schneiderhan-Marra N, Templin MF, Joos TO, Kowalewski DJ, Stos-Zweifel V, Fehr M, Rabsteyn A, Mirakaj V, Karbach J, Jäger E, Graf M, Gruber LC, Rachfalski D, Preuß B, Hagelstein I, Märklin M, Bakchoul T, Gouttefangeas C, Kohlbacher O, Klein R, Stevanović S, Rammensee HG, Walz JS

  • 2020

    Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma

    Bilich T, Nelde A, Bauer J, Walz S, Roerden M, Salih HR, Weisel K, Besemer B, Marcu A, Lübke M, Schuhmacher J, Neidert MC, Rammensee HG, Stevanović S, Walz JS

  • 2019

    The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy

    Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS

  • 2016

    Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini

    Kowalewski DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig SM, Kanz L, Salih HR, Rammensee HG, Stevanović S, and Stickel JS

  • 2015

    The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell based immunotherapy

    Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S

  • 2015

    HLA ligandome analysis identifies the underlying specificities of spontaneous anti-leukemia immune responses in CLL

    Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanović S, Stickel JS

  • 2015

    Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.

    Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS

Contact{element.contextual_1.children.icon}: Prof. Dr. med. Juliane Walz Group Leader

More about the person

Laboratory{element.contextual_1.children.icon}: +49 7071-29 78685



Certificates and Associations

Go to the main content